• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    McKesson Corporation Declares Quarterly Dividend

    10/31/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024.

    About McKesson Corporation

    McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241030704803/en/

    Get the next $MCK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

      9/24/24 8:19:53 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MCK
    SEC Filings

    See more

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal

      7/30/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

      McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

      6/26/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson to Host Investor Day on September 23, 2025

      McKesson Corporation (NYSE:MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson's leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company's strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along with the company's slide presentation will be available on McKesson's Investor Relations website at investor.mckesson.com, where you can find a complete listing of upcoming events, including details and updates. About McKesson Corporati

      6/11/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 144 filed by McKesson Corporation

      144 - MCKESSON CORP (0000927653) (Subject)

      7/11/25 10:43:52 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by McKesson Corporation

      DEFA14A - MCKESSON CORP (0000927653) (Filer)

      7/2/25 4:18:08 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by McKesson Corporation

      DEFA14A - MCKESSON CORP (0000927653) (Filer)

      6/20/25 4:26:12 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $13,716,411 worth of shares (19,371 units at $708.09), decreasing direct ownership by 41% to 27,872 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      7/14/25 4:51:43 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. gifted 4,000 shares, decreasing direct ownership by 8% to 47,243 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      6/11/25 2:05:11 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $13,673,864 worth of shares (19,370 units at $705.93), decreasing direct ownership by 27% to 51,243 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      6/9/25 3:28:44 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    See more
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals
    • Gentherm Announces Dr. Ken Washington as New Independent Director

      NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

      10/2/23 8:00:00 AM ET
      $AMZN
      $F
      $MCK
      $MDT
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Other Pharmaceuticals

    $MCK
    Financials

    Live finance-specific insights

    See more
    • McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal

      7/30/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

      McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

      6/26/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of Core Ventures

      Strengthens Community-Based Oncology Care with Florida Cancer Specialists & Research Institute Core Ventures McKesson Corporation (NYSE:MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling intere

      6/3/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      1/25/24 1:48:52 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/10/22 8:27:59 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care